Compare General Motors Company (GM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Twist Bioscience Corp — how do they compare? General Motors Company trades at $77.26 (market cap $70.01B), while Twist Bioscience Corp trades at $91.45 (market cap $5.76B). The key difference: General Motors Company is far larger — about 12.2× Twist Bioscience Corp's market cap, and General Motors Company pays a 0.93% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GM | TWST | |
|---|---|---|
Market Cap | $70.01B | $5.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $102.88 |
52-Week Low | $48.89 | $24.16 |
Enterprise Value | $173.34B | $5.69B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.87, up 0.2% daily, with a neutral technical signal. The company shows strong operational cash flow of $26.87B in 2025 and has beaten earnings estimates for three consecutive quarters. Valuation metrics appear attractive with P/S of 0.4 and P/B of 1.12, while analyst consensus remains bullish with a $102 price target representing 33% upside potential.
GM presents a value opportunity with depressed valuation multiples despite recent earnings beats and solid cash generation. Key risks include declining profit margins (1.38% net margin in 2025), competitive pressures in the EV transition, and elevated debt levels. The stock's appeal hinges on margin stabilization and successful execution of strategic initiatives amid industry headwinds.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
